

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016901 A1

(51) International Patent Classification⁷: **C07D 295/06**,
C12P 7/02, 41/00, A61K 31/495, A61P 25/18

(21) International Application Number:
PCT/DK2004/000546

(22) International Filing Date: 18 August 2004 (18.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2003 01180 18 August 2003 (18.08.2003) DK
60/496,058 18 August 2003 (18.08.2003) US
PA 2003 01305 11 September 2003 (11.09.2003) DK
60/520,246 14 November 2003 (14.11.2003) US

(71) Applicant (for all designated States except US): **H. LUNDBECK A/S** [DK/DK]; Ottiliavej 9, DK-2500 Valby-Copenhagen (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BANG-ANDERSEN, Benny** [DK/DK]; Lillegrund 33, DK-2300 Copenhagen S (DK). **BØGESØ, Klaus, Peter** [DK/DK]; Hørsholm Park 16, 2tv, DK-2970 Hørsholm (DK). **JENSEN, Klaus, Gjervig** [DK/DK]; Sofiegade 10, 2. mf., DK-1418 Copenhagen K (DK). **SVANE, Henrik** [DK/DK]; Skodsborgvej 12, DK-4296 Virum (DK). **DAHL, Allan, Carsten** [DK/DK]; Vielstedvej 8, DK-4296 Nyrup (DK).

HOWELLS, Mark [GB/DK]; Ulvemossevej 1B, DK-4622 Havdrup (DK). **LYNGSØ, Lars, Ole** [DK/DK]; Aldershvilevej 121A, st, th., DK-2880 Bagsværd (DK). **MOW, Tomas** [DK/DK]; Kæderupvej 13, DK-4682 Tureby (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: *TRANS*-1(6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPYPERAZINE

(57) Abstract: A compound 4-((1*R*,3*S*)-6-Chloro-3-phenylindan-1-yl)-2,2-dimethylpyperazine and salts thereof, pharmaceutical compositions comprising the compound and salts, and medical use thereof, including for treatment of schizophrenia and other psychotic disorders.




WO 2005/016901 A1

TRANS-1-(6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE

The present invention relates to *trans*-1-(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine and salts thereof, in particular for medical use, including for treatment of
5 schizophrenia or other diseases involving psychotic symptoms.

Background of the Invention

The compound, which is the subject of the present invention (Compound I, *trans*-1-((1*R*,3*S*)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine) has the general formula (I).



(I)

10

A group of compounds structurally related to Compound I, i.e. *trans* isomers of 3-aryl-1-(1-piperazinyl)indanes substituted in the 2- and/or 3-position of the piperazine ring, has been described in EP 638 073; Bøgesø et al. in J. Med. Chem., 1995, 38, 4380-4392 and Klaus P. Bøgesø in "Drug Hunting, the Medicinal Chemistry of 1-Piperazino-3-phenylindans and
15 Related Compounds", 1998, ISBN 87-88085-10-4I. These compounds are described as having high affinity for dopamine (DA) D₁ and D₂ receptors and the 5-HT₂ receptor and are suggested to be useful for treatment of several diseases in the central nervous system, including schizophrenia.

20 An enantiomer corresponding to the compound of the formula (I) but differing in that it has a methyl group instead of a hydrogen on the piperazine has been disclosed in Bøgesø et al. in J. Med. Chem., 1995, 38, 4380-4392, see table 5, compound (-)-38. This publication concludes that the (-)-enantiomers of compound 38 is a potent D₁/D₂ antagonists showing some D₁ selectivity in vitro while in vivo it is equipotent as D₁ and D₂ antagonist. The

compound is described as a potent 5-HT₂ antagonist, having high affinity for α_1 adrenoceptors.

None of the above references disclose the specific enantiomeric form above (Compound I) or the medical use thereof. The trans isomer in the form of the racemate of Compound 1 is only indirectly disclosed as an intermediate in the synthesis of compound 38 in Bøgesø et al. in *J. Med. Chem.*, 1995, 38, 4380-4392) while the medical use of Compound I or of its corresponding racemate is not described.

The aetiology of schizophrenia is not known, but the dopamine hypothesis of schizophrenia (Carlsson, *Am. J. Psychiatry* **1978**, 135, 164-173), formulated in the early 1960s, has provided a theoretical framework for understanding the biological mechanisms underlying this disorder. In its simplest form, the dopamine hypothesis states that schizophrenia is associated with a hyperdopaminergic state, a notion which is supported by the fact that all antipsychotic drugs on the market today exert some dopamine D₂ receptor antagonism (Seeman *Science and Medicine* **1995**, 2, 28-37). However, whereas it is generally accepted that antagonism of dopamine D₂ receptors in the limbic regions of the brain plays a key role in the treatment of positive symptoms of schizophrenia, the blockade of D₂ receptors in striatal regions of the brain causes extrapyramidal symptoms (EPS). As described in EP 638 073 a profile of mixed dopamine D₁/D₂ receptor inhibition has been observed with some so-called "atypical" antipsychotic compounds, in particular with clozapine, used in treatment of schizophrenic patients. Central α_1 antagonistic actions has also been suggested to contribute in improving antipsychotic properties (Millan *et al*, *JPET*, **2000**, 292, 38-53).

Further, selective D₁ antagonists have been connected to treatment of sleep disorders and alcohol abuse (D.N.Eder, *Current Opinion in Investigational Drugs*, **2002** 3(2):284-288). Dopamine may also play an important role in the etiology of affective disorders (P. Willner, *Brain. Res. Rev.* **1983**, 6, 211-224, 225-236 and 237-246; *J. Med. Chem.* 1985, 28, 1817-1828).

In EP 638 073 is described how compounds having affinity for 5-HT₂ receptors, in particular 5-HT₂ receptors antagonists, have been suggested for treatment of different diseases, such as

schizophrenia including the negative symptoms in schizophrenic patients, depression, anxiety, sleep disturbance, migraine attacks and neuroleptic-induced parkinsonism. 5-HT₂ receptor antagonism has also been suggested to reduce the incidence of extrapyramidal side effects induced by classical neuroleptics (Balsara et al. *Psychopharmacology* **1979**, 62, 67-69).

DETAILED DESCRIPTION OF THE INVENTION

The products of the invention and the medical use thereof

The inventors have found that Compound I displays high affinity for dopamine D1 receptors, dopamine D2 receptors and for α_1 adrenoceptors. Furthermore, compound I has been found to be an antagonist at dopamine D1 and D2 receptors, and at serotonin 5-HT_{2a} receptors. The pharmacological activities of compound I are with respect to these receptors found to be similar to that of the compound described above differing structurally from Compound I in that it has a methyl group instead of a hydrogen on the piperazine.

The inventors have also found that several of the structurally related compounds, both racemates and enantiomers, described in the above mentioned references are CYP2D6 (Cytochrome P450 2D6) inhibitors whereas Compound I is a relatively weak inhibitor of CYP2D6, also in comparison with other antipsychotics such as Haloperidole and Risperidone. The racemate of the compound of the present invention is also considerable more potent on the CYP2D6 enzyme compared to the enantiomer of the present invention, i.e. Compound I.

The CYP2D6 enzyme is a liver enzyme important for metabolism. CYP2D6 is a mammalian enzyme commonly associated with the metabolism of pharmaceutical compounds and inhibition of this drug metabolizing enzyme may lead to clinically significant drug-drug interactions i.e. if two drugs are given in combination and are metabolised by the same enzymes, competition for metabolism may give rise to increased plasma concentrations and therefore possible adverse effects (for review see Lin et al, *Pharmacological Rev.* **1997**, 49, 403-449, Bertz RJ and Granneman GR. *Clin Pharmacokinet* **1997**, 32, 210-258).

Since more than 80 drugs in clinical use (and in particular psychotropic drugs) are metabolized by CYP2D6 (Bertz RJ, Granneman GR. *Clin Pharmacokin* 1997, 32, 210-58, Rendic S, DiCarlo FJ. *Drug Metab Rev* 1997, 29, 413-580), inhibition of this enzyme by
5 coadministered drugs can lead to dramatic increases in exposure levels and resulting toxicity as seen with the combination of the well known CYP2D6 inhibitors fluoxetine or paroxetine in combination with Imipramine, Desimipramine or Nortriptyline, resulting in increased cardiac toxicity of these tricyclics (Ereshefsky L. et al. *J. Clin. Psychiatry* 1996, 57(suppl8), 17-25, Shulman RW *Can J Psychiatry*, Vol 42, Supplement 1, 4S).


10

The fact that Compound I has a low interaction with the liver enzyme CYP2D6 means that it has a reduced potential for drug to drug interaction, i.e. there is possibly less drug to drug interaction when a patient is treated with the compound of the present invention together with other drugs which are mainly metabolised by the CYP2D6 enzyme. This is a
15 considerable advantage, in particular for patients with schizophrenia which are often treated with other medicaments to control their disease.

20

The inventors have also found that Compound I has a relatively low prolonging effect on the QT-interval in the electrocardiogram (ECG) of the "alpha-chloralose anaesthetised rabbit".
Drug-induced QT-interval prolongation in the electrocardiogram (ECG) and the appearance of fatal cardiac arrhythmias, torsade de pointes (TdP), has become recognised as a potential risk during treatment with a broad range of drugs including repolarisation-delaying antiarrhythmics [C.L. Raehl, A.K. Patel and M. LeRoy, *Clin Pharm* 4 (1985), 675-690], various antihistamines [R.L. Woosley, *Annu Rev Pharmacol Toxicol* 36 (1996), 233-252;
25 Y.G. Yap and A.J. Camm, *Clin Exp Allergy* 29 Suppl 1 (1999), 15-24], antipsychotics [A.H. Glassman and J.T. Bigger, *Am J Psychiatry* 158 (2001), 1774-1782] and antimicrobial agents [B. Darpö, *Eur Heart J* 3 Suppl K (2001), K70-K80]. The fact that Compound I has a relatively low effect on the rabbit QT interval means that this compound has a reduced potential for introducing drug-induced QT interval prolongation and
30 appearance of fatal cardiac arrhythmias, torsade de pointes (TdP), in humans compared to several commercialised antipsychotics.

Thus, in one aspect, the invention relates to the compound of formula I (Compound I) and salts thereof. The salt of the invention, i.e. of the compound of formula (I), may, e.g., be selected from a fumarate or a maleate salt of Compound I.



(I)

5

The properties of Compound I indicate that it will be particularly useful as a pharmaceutical. Accordingly, the present invention further relates to a pharmaceutical composition of Compound I of the invention or a salt thereof. The invention also relates to the medical use
10 of such compounds, salts and compositions, such as for the treatment of a disease in the central nervous system, including psychosis, in particular schizophrenia or other diseases involving psychotic symptoms, such as, *e.g.*, Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder as well other psychotic disorders or diseases that present with psychotic symptoms,
15 *e.g.* mania in bipolar disorder.

Additionally, the 5-HT₂ antagonistic activity of the compound of the invention suggests that the compound or salt thereof may have a relatively low risk of extrapyramidal side effects.

20 The present invention also relates to use of Compound I of the invention, or a salt thereof for treatment of a disease selected from the group consisting of anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, cocaine abuse, nicotine abuse, alcohol abuse and other abuse disorders.

25 In a preferred embodiment, the present invention relates to a method of treating Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic

Disorder, Shared Psychotic Disorder or mania in bipolar disorder, comprising administering a therapeutically effective amount of Compound I of the invention or a salt thereof.

5 A further embodiment of the invention relates to a method of treating positive symptoms of schizophrenia comprising administering a therapeutically effective amount of Compound I or a salt thereof.

10 Another embodiment of the invention relates to a method of treating negative symptoms of schizophrenia comprising administering a therapeutically effective amount of the Compound I or a salt thereof.

15 A further embodiment of the invention relates to a method of treating depressive symptoms of schizophrenia comprising administering a therapeutically effective amount of Compound I or a salt thereof.

A further aspect of the invention relates to a method of treating mania and/or maintenance of bipolar disorder comprising administering a therapeutically effective amount of Compound I or a salt thereof.

20 A further aspect of the invention relates to a method of treating neuroleptic-induced parkinsonism comprising administering a therapeutically effective amount of the Compound I or a salt thereof.

25 The invention further relates to a method of treating substance abuse, *e.g.* nicotine, alcohol or cocaine abuse, comprising administering a therapeutically effective amount of Compound I or a salt thereof.

In a broad aspect, the present invention relates to *trans*-1-(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine or a salt thereof for use as a medicament.

30 Accordingly, the present invention also relates to a method of treating a disease selected from the group consisting of a disease involving psychotic symptoms, schizophrenia (*e.g.*

one or more of positive symptoms, negative symptoms and depressive symptoms of schizophrenia), Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and mania in bipolar disorder, anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, and abuse disorders, e.g. cocaine abuse, nicotine abuse, or alcohol abuse, comprising administering a therapeutically effective amount of the compound *trans*-1-(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine or a salt thereof.

As used herein the term "*trans*-1-(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine", i.e. without any specific indication of the enantiomer form (e.g. using (+) and (-), or using the R/S-convention, is meant to refer to any enantiomeric form of this compound, i.e. either of the two enantiomers or to a mixture of the two, e.g. the racemic mixture). However, in this context preferably the content of the enantiomer corresponding to that of Compound I is at least 50%, i.e. at least as the racemic mixture, but preferably Compound I is in enantiomeric excess.

In the present context for the pharmaceutical uses it is understood that when specifying the enantiomer form as done in formula (I) for Compound I, then the compound is relatively stereochemically pure, preferably the enantiomeric excess is of at least 70%, and more preferably at least 80% (80% enantiomeric excess means that the ratio of I to its enantiomer is 90:10 in the mixture in question) at least 90%, at least 96%, or preferably at least 98%. In a preferred embodiment, the diastereomeric excess of Compound I is at least 90% (90% diastereomeric purity means the ratio of Compound I to *cis*-1-((1*S*,3*S*)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine is 95:5), at least 95%, at least 97%, or at least 98%.

A further aspect of the invention relates to a method of treatment as described herein, wherein the patient treated with Compound I or a salt thereof is also treated with at least one other medicament. A particular relevant embodiment in this connection, is treatment with other medicaments being metabolised by CYP2D6.

In a suitable embodiment, the other medicament is an antipsychotic. Accordingly, one embodiment relates to the use of a compound, salt or pharmaceutical composition of the invention for treating a patient suffering from schizophrenia or other psychoses who is also treated with other medicament(s), e.g. where this other medicament is an antipsychotic.

5

In another embodiment, the invention relates to the use of a compound or a salt of the invention for treating a patient suffering from schizophrenia or other psychoses who is a substance abuser, e.g. of alcohol or narcotics.

- 10 The compound, salt or composition of the invention may be administered in any suitable way *e.g.* orally, buccal, sublingual or parenterally, and the compound or salt may be presented in any suitable form for such administration, *e.g.* in the form of tablets, capsules, powders, syrups or solutions or dispersions for injection. In one embodiment, the compound or salt of the invention are administered in the form of a solid pharmaceutical entity, suitably
- 15 as a tablet or a capsule.

Methods for the preparation of solid pharmaceutical preparations are well known in the art. Tablets may thus be prepared by mixing the active ingredient with ordinary adjuvants, fillers and diluents and subsequently compressing the mixture in a convenient tableting machine.

- 20 Examples of adjuvants, fillers and diluents comprise corn starch, lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive such as colourings, aroma, preservatives, etc. may also be used provided that they are compatible with the active ingredients.

- 25 Solutions for injections may be prepared by dissolving a salt of the invention and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilisation of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, solubilising agents etc.

30

The daily dose of the compound of formula (I) above, calculated as the free base, is suitably between 1.0 and 160 mg/day, more suitable between 1 and 100 mg, *e.g.* preferably between 2 and 55 mg.


- 5 The term "treatment" as used herein in connection with a disease or disorders includes also prevention as the case may be.

Method of preparation

10 The compound of formula (I) in racemic form may, *e.g.*, be prepared analogously to the methods outlined in EP 638 073, and in Bøgesø et al. J. Med. Chem., 1995, 38, page 4380-4392 followed by optical resolution of the racemic compound by crystallisation of diastereomeric salts thereby obtaining the enantiomer of formula (I).

The present inventors have developed a route of synthesis in which the enantiomer of formula (I) is obtained via a synthetic sequence starting from enantiomeric pure V, *i.e.* compound Va ((1*S*,3*S*)-6-chloro-3-phenylindan-1-ol, see below). Thus, in this process, the intermediate of formula V is resolved, *e.g.* by chiral chromatography or enzymatically, to obtain the enantiomer of formula Va. This new route of synthesis to obtain the compound of formula (I) is more efficient than the above mentioned crystallisation of diastereomeric salts of the final product I, *e.g.* the resolution of an intermediate instead of the final product gives
20 a much more efficient synthesis, as only the wanted enantiomer is used in the subsequent steps, giving *e.g.* higher volume yields and less consumption of reagents.

Accordingly, the enantiomer of formula (I) may be obtained by a process involving the following steps:




25


Benzyl cyanide is reacted with 2,5-dichlorobenzonitril in the presence of a base, suitably potassium tert-butoxide (t-BuOK) in a suitable solvent such as dimethyl ether (DME),

further reaction with methyl chloro acetate (MCA) leads to spontaneous ring closure and one pot formation of the compound of formula (II).


- The compound of formula (II) is then subjected to acidic hydrolysis to form a compound of formula (III), suitably by heating in a mixture of acetic acid, sulphuric acid and water, and thereafter decarboxylation by heating the compound of formula (III) in a suitable solvent, such as toluene with triethyl amine or N-methyl pyrrolidin-2-one (NMP), to form a compound of formula (IV).



- The compound of formula (IV) is then reduced, suitably with sodium borohydride (NaBH_4) in a solvent such as an alcohol, *e.g.* ethanol or *iso*-propanol, and preferably at a temperature in the range of -30° to $+30^\circ\text{C}$, *e.g.* below 30°C , below 20°C , below 10°C , or preferably below 5°C , to form a compound of formula (V) with *cis* configuration:




- The compound of formula (V) is resolved to achieve the desired enantiomer (formula Va), *i.e.* also with *cis* configuration ((*1S,3S*)-6-chloro-3-phenylindan-1-ol):



The resolution of (V) to (Va) may, *e.g.*, be performed using chiral chromatography, preferably liquid chromatography, suitably on a chiral column of silicagel coated with a chiral polymer, *e.g.* a modified amylose, preferably amylose tris-(3,5-dimethylphenylcarbamate) coated on silicagel. A suitable solvent is used for the chiral liquid chromatography, such as, *e.g.* an alcohol, a nitrile, an ether, or an alkane, or mixtures thereof, suitably ethanol, methanol, iso-propanol, acetonitrile, or methyl tert-butyl ether or mixtures thereof, preferably methanol or acetonitrile. The chiral liquid chromatography can be scaled up using suitable technologies, *e.g.* simulated moving bed technology (SMB).

Alternatively, the compound of formula (V) is resolved to achieve Compound Va by enzymatic resolution. It has been found that enantiomerically pure Compound Va, or acylated derivatives thereof, may be prepared by enzymatic enantioselective acylation of the hydroxyl group in racemic Compound V to obtain Compound Va or an acylated derivative thereof with high optical purity. Alternatively, enantiomerically pure Compound Va may also be obtained by a process comprising converting racemic Compound V to the corresponding ester derivative, i.e. an ester group at the hydroxyl position followed by an enzymatic enantioselective deacylation. Use of enzymatic enantioselective deacylation has been reported for other compounds.


Accordingly, the resolution of Compound V to Compound Va may be performed by selective enzymatic acylation. Selective enzymatic acylation means that the enzymatic acylation is preferentially effective for conversion of one of the *cis*- enantiomers of the compound of formula V to the corresponding acetylated derivative Vb leaving the other *cis*- enantiomer of Compound V, *e.g.* compound Va, as unconverted in the reaction mixture as outlined in the following:



wherein R, *e.g.*, is acetate, propionate, butyrate, valerate, hexanoate, benzoate, laurate,
 5 isobutyrate, 2-methylbutyrate, 3-methylbutyrate, pivalate, 2-methylvalerate, 3-methylvalerate, or 4-methylvalerate. Suitable irreversible *acyldonors* are, *e.g.*, vinyl-esters, 2-propenyl-esters or 2,2,2-trihaloethyl-esters. Alternatively, the other enantiomer is acetylated (i.e. acetylated Va is the product, not shown), and the alcohol Va can subsequently be obtained by isolation of acetylated Va and subsequent removal of the ester
 10 group.

Alternatively, The resolution of Compound V to Compound Va may be performed by selective enzymatic deacylation. Selective enzymatic deacylation means that the enzymatic deacylation is preferentially effective for conversion of one of the esters of compound of
 15 formula V (Vc), leaving the other *cis*-enantiomer of esters of a compound of formula V (Vd) as unconverted in the reaction mixture.

Suitable esters (Vc) of the compound of formula (V) are esters such as acetate, propionate, butyrate, valerate, hexanoate, benzoate, laurate, isobutyrate, 2-methylbutyrate, 3-methylbutyrate, pivalate, 2-methylvalerate, 3-methylvalerate, 4-methylvalerate,
 20 methylbutyrate, pivalate, 2-methylvalerate, 3-methylvalerate, 4-methylvalerate,



wherein R¹, *e.g.*, is acetate, propionate, butyrate, valerate, hexanoate, benzoate, laurate, isobutyrate, 2-methylbutyrate, 3-methylbutyrate, pivalate, 2-methylvalerate, 3-

methylvalerate, or 4-methylvalerate. Alternatively the ester of Va is left unconverted in the reaction mixture (i.e. acetylated Va is the product, not shown) and the alcohol Va can subsequently be obtained by isolation of acetylated Va and subsequent removal of the ester group by standard procedures.

5

Thus, enantioselective enzymatic *acylation* means that the enzymatic acylation is preferentially effective for conversion of one of the enantiomers of a compound of formula (V) preferentially leaving the other enantiomer of the compound of formula (V) unconverted in the reaction mixture. Enantioselective enzymatic *deacylation* means that the enzymatic

10 deacylation is preferentially effective for conversion of one of the enantiomers of a compound of formula (Vc), preferentially leaving the other enantiomer of the compound of formula (Vc) unconverted in the reaction mixture.

Thus, one embodiment relates to a process for the preparation of the (S, S)- or (R, R)-

15 enantiomer of the compound of formula V (i.e. with *cis* configuration) comprising:

- a) subjecting a racemic Compound V to enantioselective enzymatic acylation using an acylating agent, or
- b) subjecting a racemic Compound Vc to entantioselective enzymatic deacylation to form a mixture of deacylated Compound Va.

20

The mixtures obtained by the enzymatic resolution may not be entirely pure, *e.g.* they may contain a smaller amount of the other enantiomer in addition to a larger amount of the desired enantiomer (Va). The composition mixture obtained after acylation or deacylation according to the invention depend, *e.g.*, on the specific hydrolase used and the conditions

25 under which the reaction is carried out. Characteristic of the enzymatic acylation/deacylation according to the invention is that a considerably larger portion of one enantiomer is converted than of the other. The enantioselective *acylation* according to the invention thus results in a mixture containing preferentially the compound of formula (Vb) in the (R, R) - form and the compound of formula (Va) in the (S, S)-form, or it may result in a mixture

30 containing preferentially the compound of formula (Vb) in the (S, S)-form and the compound of formula (Va) in the (R, R)-form. Likewise, the enantioselective enzymatic *deacylation* may result in a mixture containing preferentially the compound of formula (Vd)

in the (S, S)-form and the compound of formula (Va) in the (R, R)-form, or it may result in a mixture containing preferentially the compound of formula (Vd) in the (R, R)-form and the compound of formula (Va) in the (S, S)-form. The optical purity of the Va obtained by the optical resolution method of the present invention is usually at least 90% ee., preferably at least 95% ee., more preferably at least 97% ee and most preferably at least 98% ee. However, lower values for the optical purity are acceptable.


According to the invention, enantioselective enzymatic *acylation* is carried out under conditions substantially suppressing hydrolysis. Hydrolysis, which is the reverse reaction of the acylation reaction, takes place if water is present in the reaction system. Thus, enantioselective enzymatic acylation is preferably carried out in a water-free organic solvent or almost anhydrous organic solvent (enzymes normally require the presence of some water to be active). Suitable solvents include hydrocarbons such as hexane, heptane, benzene and toluene; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, 1,4-dioxane, tert-butyl methyl ether and dimethoxyethane; ketones such as acetone, diethyl ketone, butanon, and methyl ethyl ketone; esters such as methyl acetate, ethyl acetate, ethyl butyrate, vinyl butyrate and ethyl benzoate; halogenated hydrocarbons such as methylene chloride, chloroform and 1,1,1-trichloroethane; secondary and tertiary alcohols, such as tert-butanol; nitrogen-containing solvents such as dimethylformamide, acetoamide, formamide, acetonitrile and propionitrile; and aprotic polar solvents such as dimethylsulfoxide, N-methylpyrrolidin-2-one and hexamethylphosphorous triamide. Preferred organic solvents for enzymatic acylation are organic solvents such as toluene, hexane, heptane, dioxane and tetrahydrofuran (THF).

Suitable irreversible *acyldonors* are, e.g., acyldonors such as vinyl-esters, 2-propenyl-esters or 2,2,2-trihalid-ethyl-esters.

Enantioselective enzymatic *deacylation* is preferably carried out in water or a mixture of water and an organic solvent, suitable in presence of a buffer. Suitable organic solvents, e.g., are solvents miscible with water such as alcohols, acetonitrile, dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, DME and diglyme.


It has been found that enzymatic acylation according to the invention may be carried out using Novozym 435 (Candida Antarctica lipase B, from Novozymes A/S, Fluka Cat.-No. 73940). In general, the enzymatic acylation or deacylation according to the invention is preferably carried out using a lipase, an esterase, an acylase or a protease. The enzymes
5 useful according to the invention are such enzymes capable of performing R-selective acylation or S-selective acylation of the hydroxy group in the racemic compound of formula (V) or such enzymes which are capable of performing R-selective deacylation or S-selective deacylation of the acyl group in the racemic compound of formula (Vc). In particular immobilized forms of the enzyme, including Cross-Linked Enzyme Crystal (CLEC) are
10 useful according to the invention. A preferred embodiment relates to use of a lipase for carrying out the enzymatic resolution of Compound V. The most preferred lipase is Candida antarctica lipase (Fluka Cat.-No. 62299); Pseudomonas cepacia lipase (Fluka Cat.-No. 62309); Novozym CALB L (Candida antarctica lipase B) (Novozymes A/S); Novozym 435 (Candida antarctica lipase B) (Novozymes A/S); or Lipozyme TL IM (Thermomyces
15 lanuginosus lipase) (Novozymes A/S), preferably in immobilized form.

The alcohol group of the *cis*-alcohol of formula (Va) is converted to a suitable leaving group, such as, *e.g.*, a halogen, *e.g.* Cl or Br, preferably Cl, or a sulphonate, *e.g.* mesylate or tosylate, suitably by reaction with an agent, such as thionyl chloride, mesyl chloride or tosyl
20 chloride, in an inert solvent, *e.g.* an ether, suitably tetrahydrofuran. The resulting compound has formula (VI), where LG is the leaving group:



In a preferred embodiment, LG is Cl, i.e. the *cis*-chloride of formula (VIa):

16




(VIa)

Compound VI, *e.g.* with LG as chloro, is then reacted with 2,2-dimethylpiperazine in a suitable solvent, *e.g.* a ketone such as, *e.g.*, methyl isobutyl ketone or methyl ethyl ketone, preferably methyl isobutyl ketone in presence of a base, such as *e.g.*, potassium carbonate, to


5

Furthermore, the piperazine part of the molecule may be introduced by reacting Compound VI with a compound of formula (VII) below, where PG is a protecting group such as, but not restricted to, *e.g.* phenylmethoxycarbonyl (often called Cbz or Z), tert-butyloxycarbonyl (often called BOC), ethoxycarbonyl, or benzyl, thereby obtaining the compound of formula

10



(VII)



(VIII)

During the synthesis some *cis* diastereoisomer of Compound I (*i.e.* 1-(((1*S*,3*S*)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine) is formed as an impurity in the final product. This impurity is due mainly to the formation of some of the *trans* form of (VI) (*e.g.* (1*S*,3*R*)-3,5-dichloro-1-phenylindan when LG is Cl) in the step where Compound VI is formed. Therefore, the impurity can be minimized by crystallisation of the desired *cis* form of Compound VI, from the mixture of *trans* and *cis* (VI); in the case where LG is Cl in

15

20


form of Compound VI goes into solution. The desired *cis* form of Compound VI (*e.g.* when LG is Cl) is isolated by filtration, washed with the solvent in question and dried.

5 The *cis* form of Compound I may also be removed by precipitation of a suitable salt of the compound of formula Compound I, *e.g.* a salt of an organic acid, such as an organic diacid, suitably a fumarate salt or a maleate salt of the compound of formula (I), optionally followed by one more re-crystallisations.

10 The invention in further aspects also relates to the intermediates as described herein for the synthesis of the compound of formula (I), *i.e.* in particular the intermediates Va and VI, including Compound VIa. In this context is understood that when specifying the stereoisomeric form, then the stereoisomer is the main constituent of the compound. In particular, when specifying the enantiomeric form, then the compound has an enantiomeric excess of the enantiomer in question.


15 Accordingly, one embodiment of the invention relates to the compound of formula (Va), preferably having an enantiomeric excess of at least 60% (60% enantiomeric excess means that the ratio of Va to its enantiomer is 80:20 in the mixture in question), at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%. Furthermore, the
20 diastereomeric excess of the compound is preferably at least 70% (70% diastereomeric excess means, that the ratio of Compound Va to (1R,3S)-6-chloro-3-phenylindan-1-ol is 85:15 in the mixture in question), at least 80%, at least 85%, at least 90%, or at least 95%. One embodiment relates to substantially pure Compound Va.

25 A further embodiment of the invention relates to the compound of formula (VI), preferably having an enantiomeric excess of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%,



wherein LG is a potential leaving group, preferably selected from the group consisting of a halogen, *e.g.* chloride, or a sulphonate. One embodiment relates to the diastereomeric purity of Compound VI; *i.e.* the compound having a diastereomeric excess of preferably at least 10% (10% diastereomeric excess means that the ratio of Compound VI to the trans diastereoisomer (*e.g.* (1S,3R)-3,5-dichloro-1-phenylindane when LG=Cl) is 55:45 in the mixture in question), at least 25% or at least 50%. One embodiment, relates to substantially pure Compound VI.

Accordingly, the invention also relates to a compound having the following formula (VIa),



preferably having an enantiomeric excess of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%. One embodiment relates to the diastereomeric purity of the compound, *i.e.* the compound having a diastereomeric excess of, preferably at least 10% (10% diastereomeric excess means that the ratio of the compound to the trans diastereoisomer, (1S,3R)-3,5-dichloro-1-phenylindane, is 55:45 in the mixture in question), at least 25% or at least 50%. One embodiment relates to substantially pure Compound VI where LG is Cl.

As indicated above the invention in a particular interesting embodiment relates to:

- Compound I or a salt thereof,
- a pharmaceutical compositions as described herein comprising Compound I or a salt thereof,

- a medical use as described herein for Compound I or a salt thereof,
wherein Compound I is having an enantiomeric excess of at least 60% (60% enantiomeric
excess means that the ratio of Compound I to its enantiomer is 80:20 in the mixture in
question), at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at
5 least 98%.

One embodiment relates to Compound I or a salt thereof and the uses as described herein,
wherein Compound I is having a diastereomeric excess of at least 10% (10% diastereomeric
excess means that the ratio of Compound I to the cis-(1*S*,3*S*) diastereoisomer is 55:45 in the
10 mixture in question), at least 25%, at least 50%, at least 70%, at least 80%, at least 90%, at
least 95%, at least 97%, preferably at least 98%.

One embodiment relates to substantially pure Compound I or a salt thereof; also for a
medical use as described herein.

15

A further aspect relates to Compound I or a salt thereof, in particular the fumarate or maleate
salt, obtainable, in particular obtained, by a method of the invention as described herein;
also for a medical use as described herein.

20 The invention will be illustrated in the following non-limiting examples.

EXAMPLES

PHARMACOLOGY

25

Binding assays

For all assays: Results are expressed as percent inhibition of control specific binding and the
IC₅₀ values (concentration causing a half-maximal inhibition of control specific binding) are
determined by non-linear regression analysis using Hill equation curve fitting. The
30 inhibition constants (K_i) were calculated from the Cheng Prusoff equation ($K_i =$
IC₅₀/(1+(L/K_D)), where L equals the concentration of radioligand in the assay) and K_D
equals the affinity of the radioligand for the receptor.

Alpha-1 Adrenoceptors subtypes

Chinese hamster ovary (CHO) cell lines expressing rat α_{1d} and Baby hamster Kidney (BHK) cells expressing bovine α_{1a} were generated using standard stable transfection techniques. The Rat-1 cell line expressing the hamster α_{1b} receptor was obtained from University of Utah, Salt Lake City, UT. Cell lines expressing the appropriate (α_{1a} , α_{1b} , α_{1d}) receptors were harvested and homogenized in ice-cold 50 mM Tris pH 7.7 using an Ultra-Turrax homogenizer and either stored at -80°C or kept on ice until used. $[^3\text{H}]$ Prazosin (0.3-0.5 nM) was used as radioligand assessing the affinity of subtypes of α_1 receptors. Total binding was determined using assay buffer and non-specific binding was defined in the presence of 1 μM WB-4101 for all subtypes of α_1 receptors. Aliquots were incubated 20 min at 25°C . In all assays bound and free radioactivity were separated by vacuum filtration on GF/B filters pretreated with Polyethyleneimine (PEI) and counted in a scintillation counter.

Alpha-1 Adrenoceptors (Inhibition of binding of $[^3\text{H}]$ Prazosine to rat alpha-1-receptors)

By this method, the inhibition by drugs of the binding of $[^3\text{H}]$ Prazosin (0.25 nM) to α_1 receptors in membranes from rat brain is determined *in vitro*. Method modified from Hyttel et al. *J. Neurochem.* **1985**, *44*, 1615-1622.

DA D1 receptors:

Affinities towards human D1 receptors were determined at the contract laboratory Cerep using the catalog reference assay no 803-1h. Membranes from CHO cells expressing human recombinant D1 receptors were used. 0,3 nM $[^3\text{H}]$ -SCH23390 was used as radioligand and compounds were tested in a serial dilution concurrently with the reference compound SCH23390 in order to assess the assay suitability. Aliquots were incubated at 22°C for 60 min and bound radioactivity are measured with a liquid scintillation counter. Specific control binding to the D1 receptors was defined as the difference between the total binding determined without compound present and the non-specific binding determined in the presence of 1 μM SCH 23390.

30

DA D2 receptors:

CHO cells expressing approximately 800 fmol/mg human recombinant D2 receptors were generated standard stable transfection techniques. Membranes were harvested using standard protocols and affinities were measured by the addition of a serial dilution of compound to a membrane preparation in a mixture of 50 mM Tris-HCl, 120 mM NaCl, 4 mM MgCl₂. 0.1 nM ³[H]-Spiperone was used as the radioligand assessing the affinity for the human D2 receptor. Total binding was determined in the presence of buffer and non-specific binding was determined in the presence of 10 µM haloperidol. The mixture was incubated for 30 minutes at 37 °C, cooled briefly on ice. Bound and free radioactivity was separated by vacuum filtration on GF/C filters pretreated with 0.1 % Polyethyleneimine (PEI) and filters were counted in a scintillation counter.

Efficacy assays

DA D1 receptors:

The ability of the compounds to inhibit the D1 receptor mediated cAMP formation in a CHO cell line generated in-house stably expressing the human recombinant D1 receptor was measured as follows. Cells were seeded in 96-well plates at a concentration of 11000 cells/well 3 days prior to the experiment. On the day of the experiment the cells were washed once in preheated G buffer (1 mM MgCl₂, 0.9 mM CaCl₂, 1 mM IBMX in PBS) and the assay was initiated by addition of 100 µl of a mixture of 30 nM A68930 and test compound diluted in G buffer. The cells were incubated for 20 minutes at 37 °C and the reaction was stopped by the addition of 100 µl S buffer (0.1 M HCl and 0.1 mM CaCl₂) and the plates were placed at 4 °C for 1 hour. 68 µl N buffer (0.15 M NaOH and 60 mM NaAc) was added and the plates were shaken for 10 minutes. 60 µl of the reaction were transferred to cAMP FlashPlates (DuPont NEN) containing 40 µl 60 mM NaAc pH 6.2 and 100 µl IC mix (50 mM NaAc pH 6.2, 0.1 % NaAzid, 12 mM CaCl₂, 1% BSA and 0.15 µCi/ml ¹²⁵I-cAMP) were added. Following an 18-hour incubation at 4 °C the plates were washed once and counted in a Wallac TriLux counter.

DA D2 receptors:

The ability of the compounds to inhibit the D2 receptor mediated inhibition of cAMP formation in CHO cells transfected with the human D2 receptor was measure as follows.

Cells were seeded in 96 well plates at a concentration of 8000 cells/well 3 days prior to the experiment. On the day of the experiment the cells were washed once in preheated G buffer (1 mM MgCl₂, 0.9 mM CaCl₂, 1 mM IBMX in PBS) and the assay was initiated by addition of 100 µl of a mixture of 1 µM quinpirole, 10 µM forskolin and test compound in G buffer.

5 The cells were incubated 20 minutes at 37 °C and the reaction was stopped by the addition of 100 µl S buffer (0.1 M HCl and 0.1 mM CaCl₂) and the plates were placed at 4 °C for 1 hour. 68 µl N buffer (0.15 M NaOH and 60 mM NaAc) were added and the plates were shaken for 10 minutes. 60 µl of the reaction were transferred to cAMP FlashPlates (DuPont NEN) containing 40 µl 60 mM NaAc pH 6.2 and 100 µl IC mix (50 mM NaAc pH 6.2, 0.1

10 % NaAzid, 12 mM CaCl₂, 1% BSA and 0.15 µCi/ml ¹²⁵I-cAMP) were added. Following an 18-hour incubation at 4 °C the plates were washed once and counted in a Wallac TriLux counter.

Serotonin 5-HT_{2A} receptors

15 2 or 3 days before the experiment, CHO cells expressing 250 fmol/mg 5-HT_{2A} receptors are plated at a density sufficient to yield a mono-confluent layer on the day of the experiment. The cells are dye loaded (Ca²⁺-kit from Molecular Devices and using Hank's balanced salt w/o phenol red, added 20mM HEPES and pH adjusted to 7.4 with 2M NaOH as

20 assaybuffer) for 60 minutes at 37° C in a 5% CO₂ incubator at 95% humidity. Lacer intensity is set to a suitable level to obtain basal values of approximately 8000-10000 fluorescence units. The variation in basal fluorescence should be less than 10%. EC₅₀ values are assessed using increasing concentrations of test compound covering at least 3 decades. IC₅₀ values are assessed challenging the same range of concentrations of test substances with EC₈₅ of 5-HT. Test substances are added to the cells 5 minutes before the 5-HT. K_i values were

25 calculated using Cheng-Prusoff equation. % Stimulation of a concentration of the test compound is measured with respect to a maximal concentration of 5-HT (100%). % Inhibition of a concentration of the test compound is measured as the percentage with which the response of EC₈₅ of 5-HT is lowered. Maximum inhibition is the level of inhibition the curve reaches. It is expressed as the percentage inhibition at that level and used to

30 distinguish full and partial antagonists.

In vitro determination of the interaction of compounds with CYP2D6 (CYP2D6 inhibitor assay)

Principle: The inhibition of human CYP2D6 is assessed using microsomes prepared from baculovirus/insect cells cDNA expressing CYP2D6 as enzyme sources and the specific CYP2D6 substrate AMMC (3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin). AMMC is O-demethylated to AHMC (3-[2-(N,N-diethylamino)ethyl]-7-hydroxy-4-methylcoumarin) which is detected by measuring appearance of fluorescence. Preferred compounds of the present invention exhibit an IC₅₀ higher than 5 micromolar for CYP2D6 activity, the IC₅₀ being the concentration of the compound that gives 50 % of inhibition of the CYP2D6 activity.

Material and methods:

Microsomes prepared from baculovirus/insect cells cDNA expressing CYP2D6 were obtained from BD Biosciences (Gentest 456217). Fluorescence measured Ex. (405 nm) Em. (465nm) by a SpectroFluor Plus Plate Reader (Tecan Nordic). Incubations with the recombinant CYP2D6 microsomes contained 1.5 pmol of the recombinant CYP2D6 in 0.2 ml total volume 100 mM phosphate buffer at pH 7.4 containing 1.5 AMMC (3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin) with a low NADPH-regenerating system consisting of 0.0082 mM NADP⁺, 0.41 mM glucose 6-phosphate, 0.41 mM magnesium chloride and 0.4 units/ml glucose-6-phosphate dehydrogenase. The incubation time was 45 min and the incubations were quenched by addition of 0.075 ml 80 % Acetonitrile 20 % 0.5 M Tris base. All chemicals were of analytical grade from Sigma (St. Louis, MO). IC₅₀ curves were produced using 8 concentration between 40 and 0.02 micromolar of the compounds to be tested dissolved in DMSO (dimethyl sulfoxide) - final conc. in incubations were below 1.0% (Modified from N. Chauret et. al. DMD Vol. 29, Issue 9, 1196-1200, 2001). The IC₅₀ values were calculated by linear interpolation.

QT-interval

Anaesthetised rabbit:

The model described in the following was originally designed as a proarrhythmic model by Carlsson et al, [J Cardiovasc Pharmacol. 1990;16:276-85.] and has been modified to fit into screening set-up as described below under "animal preparation".

Animal preparation

Male rabbits (HsdIf:NZW, outbreed) weighing 2.0-2.8 kg were purchased from Harlan (The Netherlands). Individual body weights were measured and recorded on the day of experiment. General anaesthesia was induced via the marginal ear vein by an intravenous
5 infusion of pentobarbital (10 mg/ml, 18 mg/kg) followed by (alpha-chloralose (100 mg/kg, infusion volume 4 ml/kg administered over a 20 min period). The trachea was cannulated and the rabbits were ventilated with air at 45 strokes per min and a tidal volume of 6 ml/kg. A vascular catheter was implanted in the jugular vein for test compound administration. Additional catheters were implanted in the left carotid artery for blood sampling and blood
10 pressure monitoring. Needle electrodes were placed subcutaneously to record the standard bipolar lead II: the negative electrode was placed in front of the right shoulder, the positive electrode close to the left loin.

Experimental protocol

Following a short period of equilibration, pre-dose values were obtained at -20, -10 and 0
15 min prior to an IV bolus administration of vehicle or test compound. The effect of the bolus administration was followed for a 40 min period.

Data sampling and calculating

ECG, blood pressure and HR were continuously recorded on a Maclab 8/s using the Chart software v3.6.1 for the Macintosh computer. The sampling frequency was 1000 Hz. Effects
20 on the electrocardiogram (PQ-, QRS-, QT-, QTc-intervals and heart rate) and mean arterial blood pressure (MAP) were recorded and measured electronically.

ANALYTICAL METHODS

The enantiomeric excess of compound (Va) in Example 1a is determined by chiral HPLC
25 using a CHIRALCEL® OD column, 0.46cm ID X 25 cm L, 10µm at 40 °C. n-Hexan/ethanol 95:5 (vol/vol) is used as mobile phase at a flow rate of 1.0 ml/min, detection is performed using a UV detector at 220nm.

HPLC analysis for conversion rate used for Examples 1b:

Column: A Lichrospher RP-8 column, 250 x 4 mm (5 µm particle size)
30 Eluent: Buffered MeOH/water prepared as follows: 1.1 ml Et₃N added to 150 ml water, 10% H₃PO₄(aq) is added to pH=7 and water is added to a total of 200 ml. The mixture is added to 1.8 L MeOH.

The enantiomeric excess of compound (Va) in example 1b is determined by chiral HPLC using a CHIRALPAK® AD column, 0.46cm ID X 25 cm L, 10µm at 21 °C.

Heptane/ethanol/Diethylamine 89.9:10:0.1 (vol/vol/vol) is used as mobile phase at a flow rate of 1.0 ml/min, detection is performed using a UV detector at 220nm.

5 The enantiomeric excess of compound (I) is determined by fused silica capillary electrophoresis (CE) using the following conditions: Capillar: 50µm ID X 48.5 cm L, run buffer: 1.25mM β cyclo dextrin in 25mM sodium dihydrogen phosphate, pH 1.5, voltage: 16kV, temperature: 22°C, injection: 40mbar for 4 seconds, detection: column diode array detection 195nm, sample concentration: 500µg/ml. In this system, Compound I has a
10 retention time of approximately 10 min, and the other enantiomer has a retention time of approximately 11 min.

¹H NMR spectra is recorded at 500.13 MHz on a Bruker Avance DRX500 instrument or at 250.13 MHz on a Bruker AC 250 instrument. Chloroform (99.8%D) or dimethyl sulfoxide (99.8%D) is used as solvents, and tetramethylsilane (TMS) is used as internal reference
15 standard.

The cis/trans ratio of compound I is determined using ¹H NMR as described in Bøgesø *et al.*, *J. Med. Chem.* **1995**, 38, 4380-4392 (page 4388, right column). The *cis/trans* ratio of compound VI is determined by ¹H NMR in chloroform, using the integrals of the signal at 5.3 ppm for the *cis* isomer and the signal at 5.5 ppm for the *trans* isomer. Generally, a
20 content of approximately 1% of the undesired isomer can be detected by NMR.

The Melting points are measured using Differential Scanning Calorimetry (DSC). The equipment is a TA-Instruments DSC-2920 calibrated at 5°/min to give the melting point as onset value. About 2 mg of sample is heated 5°/min in a loosely closed pan under nitrogen flow.

25

SYNTHESIS

Synthesis of key starting material

Compound V was synthesised from IV by reduction with sodium borohydride (NaBH₄)
30 adapting a method described in Bøgesø *J. Med. Chem.* **1983**, 26, 935, using ethanol as solvent, and performing the reaction at approximately 0 °C. Both compounds are described in Bøgesø *et al. J. Med. Chem.* **1995**, 38, 4380-4392. Compound IV was synthesised from II

using the general procedures described in Sommer et al., *J. Org. Chem.* **1990**, *55*, 4822, which also describes II and the synthesis thereof.


Example 1a Synthesis of (1S,3S)-6-chloro-3-phenylindan-1-ol (Va) by use of chiral chromatography

5

Racemic *cis*-6-chloro-3-phenylindan-1-ol (V) (492 grams) is resolved by preparative chromatography, using a CHIRALPAK® AD column, 10cm ID X 50cm L, 10µm at 40 °C. Methanol is used as mobile phase at a flow rate of 190 ml/min, detection is performed using a UV detector at 287nm. The racemic alcohol (V) is injected as a 50,000 ppm solution in methanol; 90 ml is injected with intervals of 28 min. All the fractions, which contain the title compound with more than 98% enantiomeric excess, are combined and evaporated to dryness using a rotary evaporator, followed by drying "in vacuo" at 40°C. Yield 220 grams as a solid. Elemental analysis and NMR conform to the structure, the enantiomeric excess is higher than 98% according to chiral HPLC, $[\alpha]_D^{20} +44.5^\circ$ (c=1.0, methanol).

15

Example 1b Synthesis of (1S,3S)-6-chloro-3-phenylindan-1-ol (Va) by use of enzymatic resolution



V

Va

Compound V (5g, 20.4 mmol) is dissolved in 150 ml anhydrous toluene. 0.5 g Novozym 435 (*Candida Antarctica* lipase B) (Novozymes A/S, Fluka Cat.-No. 73940) is added followed by vinylbutyrate (13 ml, 102.2 mmol). The mixture is stirred using mechanical stirrer at 21 °C. After 1 day, an additional 0.5 g Novozym 435 is added. After 4 days at a conversion of 54%, the mixture is filtered and concentrated in vacuo to obtain an oil containing a mixture of (1R, 3R)-*cis*-6-chloro-3-phenylindan-1-ol-butyrates ester and desired compound Va with an enantiomeric excess of 99.2% (99.6% compound Va and 0.4% (1R, 3R)- *cis*-6-chloro-3-phenylindan-1-ol).

20

25

Example 2 Synthesis of (1*S*,3*S*)-3,5-dichloro-1-phenylindan (VI, LG=Cl)

Cis-(1*S*,3*S*)-6-chloro-3-phenylindan-1-ol (Va) (204 grams) obtained as described in Example 1a is dissolved in THF (1500ml) and cooled to -5°C. Thionyl chloride (119 grams) is added dropwise as a solution in THF (500 ml) over a period of 1 h. The mixture is stirred at room temperature over night. Ice (100 g) is added to the reaction mixture. When the ice has melted the water phase (A) and the organic phase (B) are separated, and the organic phase B is washed twice with saturated sodium bicarbonate (200 ml). The sodium bicarbonate phases are combined with water phase A, adjusted to pH 9 with sodium hydroxide (28%), and used to wash the organic phase B once again. The resulting water phase (C) and the organic phase B are separated, and the water phase C is extracted with ethyl acetate. The ethyl acetate phase is combined with the organic phase B, dried with magnesium sulphate, and evaporated to dryness using a rotary evaporator, giving the title compound as an oil. Yield 240 grams, which is used directly in the example 5. *Cis/trans* ratio 77:23 according to NMR.

Example 3 Synthesis of 3,3-dimethylpiperazin-2-one

Potassium carbonate (390 grams) and ethylene diamine (1001 grams) are stirred with toluene (1.50 l). A solution of ethyl 2-bromoisobutyrate (500 grams) in toluene (750 ml) is added. The suspension is heated to reflux over night, and filtered. The filter cake is washed with toluene (500 ml). The combined filtrates (volume 4.0 l) are heated on a water bath and distilled at 0.3 atm. using a Claisen apparatus; first 1200 ml distillate is collected at 35 °C (the temperature in the mixture is 75 °C). More toluene is added (600 ml), and another 1200 ml distillate is collected at 76 °C (the temperature in the mixture is 80 °C). Toluene (750 ml) is added again, and 1100 ml of distillate is collected at 66 °C (temperature in the mixture 71 °C). The mixture is stirred on an ice bath and inoculated, whereby the product precipitates. The product is isolated by filtration, washed with toluene, and dried over night in a vacuum oven at 50 °C. Yield 171 g (52%) of 3,3-dimethylpiperazin-2-one. NMR consistent with structure.

Example 4 Synthesis of 2,2-dimethylpiperazine

A mixture of 3,3-dimethylpiperazin-2-one (8.28 kg, 64.6 mol) and tetrahydrofuran (THF) (60 kg) is heated to 50-60 °C. giving a slightly unclear solution. THF (50 kg) is stirred under nitrogen, and LiAlH₄ (250 g, in a soluble plastic bag, from Chemetall) is added, which gives a slow evolution of gas. After gas evolution has ceased, more LiAlH₄ is added (a total of 3.0 kg, 79.1 mol, is used), and the temperature rises from 22 °C to 50 °C because of an exotherm. The solution of 3,3-dimethylpiperazin-2-one is added slowly over 2 hours at 41-59 °C. The suspension is stirred for another hour at 59 °C (jacket temperature 60 °C). The mixture is cooled, and water (3 l) is added over two hours, keeping the temperature below 25 °C (it is necessary to cool with a jacket temperature of 0 °C). Then sodium hydroxide (15%, 3.50 kg) is added over 20 minutes at 23 °C, cooling necessary. More water (9 l) is added over half an hour (cooling necessary), and the mixture is stirred over night under nitrogen. Filter agent Celit (4 kg) is added, and the mixture is filtered. The filter cake is washed with THF (40 kg). The combined filtrates are concentrated in the reactor until the temperature in the reactor is 70 °C (distillation temperature 66 °C) at 800 mbar. The remanence (12.8 kg) is further concentrated on a rotavapor to approximately 10 l. Finally, the mixture is fractionally distilled at atmospheric pressure, and the product is collected at 163-4 °C. Yield 5.3 kg (72%). NMR complies with the structure.

Example 5 Synthesis of *trans*-1-((1*R*,3*S*)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazinium (Compound I) hydrogen maleate salt

Cis-(1*S*,3*S*)-3,5-dichloro-1-phenylindan (VI, LG=Cl) (240 g) is dissolved in butan-2-one (1800 ml). Potassium carbonate (272 g) and 2,2-dimethyl piperazine (prepared in Example 4) (113 g) are added and the mixture is heated at reflux temperature for 40 h. To the reaction mixture is added diethyl ether (2 l) and hydrochloric acid (1M, 6 l). The phases are separated, and pH in the water phase is lowered from 8 to 1 with concentrated hydrochloric acid. The water phase is used to wash the organic phase once again in order to ensure, that all product is in the water phase. Sodium hydroxide (28%) is added to the water phase until pH is 10, and the water phase is extracted twice with diethyl ether (2 l). The diethyl ether extracts are combined, dried with sodium sulphate, and evaporated to dryness using a rotary evaporator. Yield 251 grams of the title compound as an oil. *Cis/trans* ratio, 82:18 according to NMR. The crude oil (ca. 20 grams) was further purified by flash chromatography on silicagel (eluent: ethyl acetate/ethanol/triethylamine 90:5:5) followed by evaporation to

dryness on a rotary evaporator. Yield 12 grams of the title compound as an oil (*cis/trans* ratio, 90:10 according to NMR). The oil is dissolved in ethanol (100 ml), and to this solution is added a solution of maleic acid in ethanol to pH 3. The resulting mixture is stirred at room temperature for 16 hours, and the formed precipitate is collected by filtration. The volume of ethanol is reduced and another batch of precipitate is collected. Yield 3.5 gram solid (no *cis* isomer is detected according to NMR) of the title compound. Enantiomeric excess is >99%. Melting point 175-178 °C. NMR complies with the structure.

Example 6 Synthesis of Compound I


10 A mixture of *trans*-1-((1*R*,3*S*)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazinium hydrogen maleate (I) (9.9 grams), concentrated aqueous ammonia (100 ml), brine (150 ml) and ethyl acetate (250 ml) is stirred at room temperature for 30 min. The phases are separated, and the aqueous phase is extracted with ethyl acetate once more. The combined organic phases are washed with brine, dried over magnesium sulphate, filtered and
15 evaporated to dryness in vacuo. Yield 7.5 grams of oil. NMR complies with the structure.

Example 7 Synthesis of *trans*-1-((1*R*,3*S*)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazinium (Compound I) fumarate salt

20 A solution of *trans*-1-((1*R*,3*S*)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine (obtained as described in example 6) (1 g) is dissolved in acetone (100 mL). To this solution is added a solution of fumaric acid in ethanol until pH of the resulting solution is 4. The resulting mixture is cooled in an ice bath for 1.5 hours whereby a precipitate is formed. The solid compound is collected by filtration. The compound was dried in vacuo giving a white
25 solid compound (1.0 g). Enantiomeric excess is >99%. Melting point 193-196 °C. NMR complies with the structure.

Claims

1. A compound of formula (Compound I, *trans*-1-((1R,3S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine)



(I)

or a salt thereof.

2. The compound or salt of claim 1 being substantially pure.

3. A pharmaceutical composition comprising the compound or salt of claim 1 or 2 together with at least one pharmaceutically acceptable carrier, filler or diluent.

4. The pharmaceutical composition according to claim 3 wherein the enantiomeric excess of Compound I is at least 90%, at least 96%, or at least 98%.

5. A compound or salt of claim 1 or 2 for use in medicine.

6. Use of a compound or salt of claim 1 or 2 in the preparation of a medicament for the treatment of a disease selected from the group consisting of a disease involving psychotic symptoms, schizophrenia, anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, and abuse disorders, *e.g.* cocaine abuse, nicotine abuse, or alcohol abuse.


7. Use of claim 6 in the preparation of a medicament for the treatment of schizophrenia or other psychotic disorders.

8. Use of claim 7 in the preparation of a medicament for the treatment of one or more of: positives symptoms, negative symptoms and depressive symptoms of schizophrenia.
- 5
9. Use of a compound or salt of claim 1 or 2 in the preparation of a medicament for the treatment of a disease selected from the group consisting of Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and mania in bipolar disorder.
- 10
- 10 The use according to any of claims 6-9, wherein said compound or salt thereof is in the form of a pharmaceutical composition as defined in claim 4.
11. A method for the treatment of a disease selected from the group consisting of a disease involving psychotic symptoms, schizophrenia, anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, or abuse disorders, *e.g.* cocaine abuse, nicotine abuse, or alcohol abuse, comprising administering a therapeutically effective amount of the compound or salt as defined in claim 1 or 2.
- 15
12. The method of claim 11 for the treatment of schizophrenia or other psychotic disorders.
- 20
13. The method of claim 12 for the treatment of one or more of: positives symptoms, negative symptoms and depressive symptoms of schizophrenia.
- 25
14. A method for the treatment of a disease selected from the group consisting of Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and mania in bipolar disorder, comprising administering a therapeutically effective amount of the compound or salt as defined in claim 1 or 2.
- 30


15. A method according to any of claims 11-14, wherein the patient treated with Compound I or a salt thereof is also treated with other medicament(s).
16. The method of claim 12, wherein the patient treated with Compound I or a salt thereof is also treated with at least one other medicament.
17. The method according to any of claims 11-16, wherein said compound or salt thereof is in the form of a pharmaceutical composition as defined in claim 4.
18. A compound *trans*-1-(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine or a salt thereof for use in medicine.
19. A pharmaceutical composition comprising the compound or salt of claim 18 together with at least one pharmaceutically acceptable carrier, filler or diluent.
20. Use of a compound or salt of claim 18 in the preparation of a medicament for the treatment of a disease selected from the group consisting of a disease involving psychotic symptoms, schizophrenia (e.g. one or more of positives symptoms, negative symptoms and depressive symptoms of schizophrenia), Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, mania in bipolar disorder, anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, abuse disorders, *e.g.* cocaine abuse, nicotine abuse, or alcohol abuse.
21. A method for the treatment of a disease selected from the group consisting of a disease involving psychotic symptoms, schizophrenia (e.g. one or more of positives symptoms, negative symptoms and depressive symptoms of schizophrenia), Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, mania in bipolar disorder, anxiety disorders, affective disorders including depression, sleep disturbances, migraine, neuroleptic-induced parkinsonism, abuse disorders, *e.g.* cocaine abuse, nicotine

abuse, or alcohol abuse, comprising administering a therapeutically effective amount of a compound or salt as defined in claim 18.

22. A method for manufacturing a compound of formula I (Compound I) or a salt thereof, which method comprises conversion of a compound of formula Va (Compound Va) in *cis*-configuration to the compound of formula I, wherein I and Va are as follows:




23. The method of claim 22, comprising conversion of the alcohol group of the *cis*-alcohol of formula Va to a suitable leaving group LG, resulting in the compound of formula VI.




24. The method of claim 23, wherein LG is a halogen, *e.g.* Cl or Br, preferably Cl, or a sulphonate.
25. The method of any of claims 22-24, wherein Compound VI is precipitated from a suitable solvent.

26. The method of claim 25, wherein LG is a halogen, preferably Cl, and the solvent is an alkane, e.g. heptane.
27. The method of any of claims 22-26, wherein Compound VI is reacted with 2,2-dimethylpiperazine to obtain Compound I.
28. The method of claim 27, wherein Compound I is precipitated as a suitable salt, *e.g.* a salt of an organic acid, such as an organic diacid.
29. The method of claim 28, wherein the formed salt is a fumarate salt or a maleate salt of Compound I.
30. The method of any of claims 22-26, comprising
- reacting Compound VI with 1-protected 2,2-dimethylpiperazine (VII), wherein PG is a protection group, *e.g.* selected from the group of phenylmethoxycarbonyl, tert-butyloxycarbonyl, ethoxycarbonyl, and benzyl, thereby obtaining a compound of formula VIII; and
 - deprotecting Compound VIII to obtain Compound I,
- wherein Compound VII and VIII are as follows:



31. A method for the preparation of Compound I or a salt thereof comprising reacting a compound of formula VIa (*i.e.* Compound VI for which LG is Cl) with 2,2-dimethylpiperazine.

32. A method for the preparation of Compound I or a salt thereof comprising reacting a compound of formula VIa



(VIa)

with 2,2-dimethylpiperazine in presence of a base.

5

33. The method of any of claims 22-32, wherein Compound Va is obtained by enzymatical resolution of Compound V.

10

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK2004/000546

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D295/06 C12P7/02 C12P41/00 A61K31/495 A61P25/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C12P A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 638 073 B (H. LUNDBECK) 21 June 2000 (2000-06-21) cited in the application page 4, line 35 - page 5, line 53; claims; examples -----	1-33
X	KLAUS P. BOGESO ET AL.: "Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindanes with Potential Atypical Antipsychotic Activity" JOURNAL OF MEDICINAL CHEMISTRY., vol. 38, no. 22, 1995, pages 4380-4392, XP008037648 USAMERICAN CHEMICAL SOCIETY. WASHINGTON. cited in the application page 4386 - page 4387; tables 5-7 -----	1-33

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

5 November 2004

Date of mailing of the international search report

17/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Zervas, B

INTERNATIONAL SEARCH REPORT

nation on patent family members

International Application No

PCT/DK2004/000546

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0638073	B	15-02-1995	AT 194003 T	15-07-2000
			AU 4059993 A	29-11-1993
			CA 2134566 A1	11-11-1993
			DE 69328901 D1	27-07-2000
			DE 69328901 T2	11-01-2001
			DK 638073 T3	06-11-2000
			EP 0638073 A1	15-02-1995
			FI 945042 A	26-10-1994
			GR 3034396 T3	29-12-2000
			HK 1013816 A1	01-12-2000
			JP 3255416 B2	12-02-2002
			JP 7505895 T	29-06-1995
			KR 267635 B1	01-11-2000
			NO 944090 A	20-12-1994
			SK 129394 A3	10-05-1995
			CZ 9402619 A3	17-05-1995
			WO 9322293 A1	11-11-1993
			ES 2148227 T3	16-10-2000
			HU 71419 A2	28-11-1995
			HU 9500587 A3	30-10-1995
			IL 105464 A	04-01-1998
			NZ 252098 A	28-05-1996
			PT 638073 T	30-11-2000
			RU 2114106 C1	27-06-1998
			US 5807855 A	15-09-1998
			ZA 9302840 A	23-11-1993